In an editorial, published in Oncoscience titled, “Entering the golden age for antibody-drug conjugates in gynecologic cancer,” researchers Michelle Greenman, Blair McNamara, Levent Mutlu, and Alessandro D. Santin from Yale University School of Medicine discuss gynecologic cancers. Biologically-aggressive tumors such as uterine serous carcinoma (USC) and carcinosarcoma (CS) are aggressive subtypes of endometrial cancer with a poor prognosis and a disproportionately high mortality rate. “Cytoreductive surgery along with chemotherapy is critical in treatment,” note the researchers. However, recurrence is common, requiring multiple lines and combinations of chemotherapy. Use of immunotherapy Read More